dr n. med. Michał Kwiatek

2013 - ukończenie studiów - kierunek lekarski, Uniwersytet Medyczny w Poznaniu
2014-2021 - kurs specjalizacyjny z hematologii, Klinika Hematologii i Transplantacji Szpiku Kostnego Uniwersytetu Medycznego w Poznaniu, zakończony uzyskaniem tytułu specjalisty
2017- aktualnie - główny badacz i współbadacz w badaniach klinicznych z zakresu hematologii, onkologii klinicznej, chorób wewnętrznych
2021 - uzyskanie tytułu doktora nauk medycznych na Uniwersytecie Medycznym w Poznaniu

Badania kliniczne:

NCT03151408
An Efficacy and Safety Study Of Pracinostat In Combination With Azacitidine In Adults With Acute Myeloid Leukemia
Phase III: Acute Myeloid Leukemia
Interventional: Recruiting

NCT03734016
A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
Phase III: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventional: Recruiting

NCT02718716
Study to Evaluate Safety, Tolerability and Efficacy of UCB7665 in Subjects With Primary Immune Thrombocytopenia
Phase II: Thrombocytopenia
Interventional: Recruiting

NCT01897571
Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Adv. Solid Tumors or With B-cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects With DLBCL
Phase I/II: B-cell Lymphomas (Phase 1), Advanced Solid Tumors (Phase 1), Diffuse Large B-cell Lymphoma (Phase 2), Follicular Lymphoma (Phase 2), Transformed Follicular Lymphoma, Primary Mediastinal Large B-Cell Lymphoma
Interventional: Recruiting

NCT03330847
To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.
Phase II: Metastatic Triple Negative Breast Cancer
Interventional: Recruiting

NCT03980041
Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)
Phase II: Bladder Cancer, Urothelial Carcinoma, Solid Tumor, Advanced Cancer
Interventional: Not yet recruiting

NCT02927262
A Study of ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete Remission
Phase III: Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) / Internal Tandem Duplication (ITD) Mutation
Interventional: Recruiting

NCT03268005
Research Study Comparing a New Medicine "Fast-acting Insulin Aspart" to Another Already Available Medicine "NovoRapid"/"NovoLog" in People With Type 2 Diabetes
Phase III: Diabetes, Diabetes Mellitus, Type 2
Interventional: Recruiting

NCT03204318
SPIRIT 1: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain
Phase III: Endometriosis Related Pain
Interventional: Recruiting

NCT03103087
LIBERTY 2: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
Phase III: Heavy Menstrual Bleeding, Uterine Fibroid
Interventional: Recruiting

NCT02545049
Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease
Phase III: Diabetic Kidney Disease
Interventional: Recruiting

NCT02540993
Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease
Phase III: Diabetic Kidney Disease
Interventional: Recruiting

NCT03496298
Effect of Efpeglenatide on Cardiovascular Outcomes in High Cardiovascular Risk Type 2 Diabetes Patients
Phase III: Type 2 Diabetes Mellitus
Interventional: Recruiting

NCT03115112
Safety and Efficacy of Bexagliflozin Compared to Sitagliptin as Add-on Therapy to Metformin in Type 2 Diabetes Subjects
Phase III: Type 2 Diabetes Mellitus
Interventional: Active, not recruiting

NCT03412890
LIBERTY EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
Phase III: Heavy Menstrual Bleeding, Uterine Fibroid
Interventional: Enrolling by invitation

NCT03751124
Study of Relugolix With Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
Phase III: Uterine Leiomyoma, Uterine Fibroids
Interventional: Enrolling by invitation

NCT03654274
SPIRIT EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Endometriosis-Associated Pain
Phase III: Endometriosis Related Pain
Interventional: Enrolling by invitation

NCT03689374
A Research Study to Compare Semaglutide to Insulin Aspart, When Taken Together With Metformin and Insulin Glargine, in People With Type 2 Diabetes
Phase III: Diabetes Mellitus, Type 2
Interventional: Not yet recruiting

NCT03204331
SPIRIT 2: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain
Phase III: Endometriosis Related Pain
Interventional: Recruiting

• Choroby hematologiczne

---

• Nowotwory

---

• Zaburzenia odporności

---

• Chłoniaki

---

• Białaczki

---

• Małopłytkowość immunologiczna

---

• Zaburzenia krzepnięcia